Uses AI and machine learning to discover antibodies for drug development, accelerating the path from target to therapy.
AbCellera Biologics Inc. operates as a leading innovator in antibody drug discovery and development, pioneering a robust platform designed to accelerate the identification of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, AbCellera harnesses advanced technologies to uncover antibodies derived from natural immune responses. These antibodies are systematically pre-enriched, enhancing the efficiency and efficacy of drug discovery processes.
At the forefront of biotechnological advancement, AbCellera boasts a portfolio of discovery programs encompassing various stages ranging from completed initiatives to ongoing projects and collaborations with esteemed partners. Notably, the company collaborates extensively with Eli Lilly and Company under a comprehensive research collaboration and license agreement. This partnership underscores AbCellera's commitment to expanding its capabilities and driving forward groundbreaking innovations in antibody-based therapeutics.
With a dedicated focus on cutting-edge research and a strong emphasis on strategic partnerships, AbCellera Biologics continues to redefine the landscape of biopharmaceuticals. By leveraging its proprietary technologies and collaborative networks, the company remains steadfast in its mission to deliver transformative antibody therapies that address unmet medical needs and improve patient outcomes worldwide.